Yiheng Capital Management L.P. lessened its position in shares of DBV Technologies S.A. (NASDAQ:DBVT - Free Report) by 79.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 656,309 shares of the company's stock after selling 2,497,267 shares during the quarter. DBV Technologies comprises 0.1% of Yiheng Capital Management L.P.'s holdings, making the stock its 16th biggest position. Yiheng Capital Management L.P. owned 3.19% of DBV Technologies worth $2,028,000 at the end of the most recent reporting period.
Analyst Ratings Changes
Several brokerages recently issued reports on DBVT. JMP Securities reaffirmed a "market outperform" rating and set a $10.00 target price on shares of DBV Technologies in a research report on Friday, January 10th. StockNews.com began coverage on shares of DBV Technologies in a research report on Saturday. They set a "hold" rating on the stock.
Read Our Latest Analysis on DBV Technologies
DBV Technologies Trading Down 10.1 %
Shares of DBVT stock traded down $0.45 during mid-day trading on Tuesday, reaching $4.01. The stock had a trading volume of 48,047 shares, compared to its average volume of 84,811. DBV Technologies S.A. has a 1-year low of $2.20 and a 1-year high of $8.32. The firm has a market cap of $82.48 million, a price-to-earnings ratio of -0.89 and a beta of 0.71. The business's fifty day moving average is $4.46 and its 200-day moving average is $3.84.
DBV Technologies Profile
(
Free Report)
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
See Also
Before you consider DBV Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DBV Technologies wasn't on the list.
While DBV Technologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
